What is the enterprise value (EV) for Halozyme Therapeutics, Inc. (HALO)?

The enterprise value (EV) for HALO stock is $14.80B.

Halozyme Therapeutics (HALO) Enterprise Value: History & Chart

Compare

Halozyme Therapeutics, Inc.(HALO)

Biotechnology · San Diego, CA

$107.85-0.46 (-0.42%)

Delayed quote: Oct 6, 2026, 10:45 AM EDT

Compare

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.

San Diego, CA

423 employees

www.halozyme.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Helen I. Torley

View full financials

NAME	MARKET CAP	ENTERPRISE VALUE (EV)
Halozyme Therapeutics, Inc. (HALO)	$12.79B	$14.80B
BridgeBio Pharma, Inc. (BBIO)vs ›	$12.93B	$14.74B
Penumbra, Inc. (PEN)vs ›	$12.51B	$12.52B
BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›	$12.50B	$14.34B
Corcept Therapeutics Incorporated (CORT)vs ›	$12.49B	$12.39B
Baxter International Inc. (BAX)vs ›	$12.46B	$19.97B
ICON Public Limited Company (ICLR)vs ›	$12.37B	$14.93B
Encompass Health Corporation (EHC)vs ›	$12.20B	$14.93B
Tempus AI, Inc. (TEM)vs ›	$13.49B	$14.34B
Ascendis Pharma A/S (ASND)vs ›	$13.98B	$13.57B

NAME

MARKET CAP

ENTERPRISE VALUE (EV)

Halozyme Therapeutics, Inc. (HALO)

$12.79B

$14.80B

BridgeBio Pharma, Inc. (BBIO)vs ›

$12.93B

$14.74B

Penumbra, Inc. (PEN)vs ›

$12.51B

$12.52B